bamzireotide navoxetan
VMT-α-NET · [212Pb]VMT-α-NET Radioligand Target: SSTR2
Perspective Therapeutics
Most recent annual filing: 2026-03-15
- Phase 3 pivotal NETs corporateyear-end 2026Phase 3 pivotal NETs corporate, year-end 2026, routine
- VMT-α-NET interimOct 23, 2026VMT-α-NET interim, Oct 23, 2026, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
lapemelanotide zapixetar
VMT01 · [212Pb]VMT01 Radioligand Target: MC1R
PSV359
[212Pb]PSV359 Radioligand Target: FAP-α
VMT-α-NET
[212Pb]VMT-α-NET Radioligand Target: SSTR2
Technology platforms
CB7-Adma · Stony Brook University
Cucurbit[7]uril-adamantane (CB7-Adma) pre-targeting platform licensed from Stony Brook University; two-step antibody-then-radionuclide delivery system targeting cancer-specific proteins; preclinical optimization underway
224Ra/212Pb generator
Proprietary 224Ra/212Pb generator platform used to manufacture clinical drug product candidates for radiopharmaceutical delivery via alpha-generating isotope 212Pb to cancer cells; supports regional finished drug product supply network for clinical and commercial operations.
Biotech Distilled coverage (16)
- 2026-09-15 UPDATE: Perspective Therapeutics (CATX) - Merck Walks In the Door Lantheus Walked Out Of 🔒 Paid
- 2026-09-04 UPDATE: Perspective Therapeutics (CATX) - Lantheus Opens the Exit Door 🔒 Paid
- 2026-08-11 UPDATE: Perspective Therapeutics (CATX) - The Phase 3 Finally Has a Dose and a Date 🔒 Paid
- 2026-07-28 UPDATE: Perspective Therapeutics (CATX) - Europe Puts a Ten-Year Fence Around the Alpha 🔒 Paid
- 2026-07-08 UPDATE: Perspective Therapeutics (CATX) - The Chemist Hands Off to the Oncology Operator 🔒 Paid
- 2026-05-22 UPDATE: Perspective Therapeutics (CATX) - The ASCO Preview Quietly Resurrects VMT01 🔒 Paid
- 2026-05-12 UPDATE: Perspective Therapeutics (CATX) - Q1 Drops Three Quiet Tells 🔒 Paid
- 2026-04-27 UPDATE: Perspective Therapeutics (CATX) - CATX Drops AACR Data 🔒 Paid
- 2026-04-05 UPDATE: Perspective Therapeutics (CATX) Dropped a Stealth De-Risking Clue Ahead of AACR 🔒 Paid
- 2026-03-21 UPDATE: Perspective Therapeutics (CATX) - The Next Catalyst is Here 🔒 Paid
- 2026-03-15 UPDATE: The CATX Institutional Land Grab Continues 🔒 Paid
- 2026-02-14 UPDATE: Perspective Therapeutics (CATX) - The Smart Money Stampede Continues 🔒 Paid
- 2026-02-07 UPDATE: Perspective Therapeutics (CATX) Just Cleared the Deck (And Smart Money Bought the Dip) 🔒 Paid
- 2026-01-13 UPDATE: Why Did Perspective Therapeutics (CATX) Just Dropped 15% (And Why It Could Be Buying Opportunity)? 🔒 Paid
- 2026-01-10 UPDATE: Perspective Therapeutics (CATX) Drops an Alpha Hammer at ASCO-GI 🔒 Paid
- 2026-01-04 Perspective Therapeutics (CATX): Scientific Deep Dive for VMT-α-NET and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.